Physician profile
Michelle L Jeffries
NPI 1669703286
$1,976.54
in general payments reported to CMS, 2019-2025
14 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2021: $134 · 2022: $187 · 2023: $482 · 2024: $498 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.35 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $308.21 | 2021-2024 | |
| Dermavant Sciences, INC. | $294.86 | 2023-2024 | Vtama |
| Pfizer INC. | $256.48 | 2019-2024 | |
| Botanix Sb INC | $136.52 | 2025 | Sofdra |
| Celgene Corporation | $124.95 | 2019 | |
| Amgen INC. | $100.30 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $68.03 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $38.65 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.11 | 2022-2023 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $24.95 | 2021 | |
| Leo Pharma INC. | $18.72 | 2025 | Anzupgo |
| Genzyme Corporation | $18.47 | 2019 | |
| Medtronic, INC. | $15.94 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Jeffries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.